Literature DB >> 26195032

[Cutaneous symptoms of various vasculitides].

C Sunderkötter1, K I Pappelbaum, J Ehrchen.   

Abstract

The skin is one of the organs most frequently involved in vasculitides. Cutaneous vasculitis may present (1) part of a systemic vasculitis (e.g., IgA vasculitis), (2) a skin-restricted or skin-dominant variant of the corresponding systemic vasculitis without clinically apparent visceral involvement (e.g., cutaneous IgA vasculitis), or (3) a vasculitis occurring exclusively in the skin (e.g., erythema elevatun diutinum). The clinical symptoms of vasculitides are markedly determined by the size of the predominantly affected blood vessels. Systemic polyarteritis nodosa is regarded as a medium vessel vasculitis and is associated with multiple skin symptoms: (1) vasculitis of digital arteries with ensuing digital infarction, (2) livedo racemosa and subcutaneous nodules, and (3) in some patients even purpura and hemorrhagic macules due to additional small vessel vasculitis. In contrast, in its skin-restricted entity (i.e., cutaneous polyarteritis nodosa), the predominant symptoms are subcutaneous nodules surrounded by livedo racemosa, often on the lower legs. Among small-vessel vasculitides palpable purpura with predilection for the legs is a nearly pathognomonic feature of immune complex vasculitis. Variations in clinical symptoms indicate additional pathophysiological mechanisms or different vascultides: (1) ANCA-associated vasculitides often also entail nodules or sometimes livedo, (2) cryoglobulinemic vasculitis additionally may present with necrosis at cold exposed areas and involvement of vessels of various size, (3) small vessel vasculitis associated with systemic lupus erythematosus or rheumatoid arthritis shows predilection for additional sites (e.g., nailfolds) and also involvement of vessels beyond postcapillary venules, (4) recurrent macular vasculitis in hypergammaglobulinemia also occurs on dependent parts, but shows numerous small hemorrhagic macules instead of palpable purpura, (5) erythema elevatum diutinum begins with brightly red to violaceous plaques at extensor sites, followed by fibrotic nodules. Consequently, cutaneous symptoms provide pivotal clues for further diagnosis and ensuing management of vasculitides.

Entities:  

Mesh:

Year:  2015        PMID: 26195032     DOI: 10.1007/s00105-015-3661-6

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  22 in total

1.  Spitting out the tongue.

Authors:  G Obermoser; L Posch; B Zelger
Journal:  Br J Dermatol       Date:  2004-09       Impact factor: 9.302

2.  Vein, artery, or arteriole? A decisive question in hypodermal pathology.

Authors:  Evaristo Sánchez Yus; Raquel S Simón; Luis Requena
Journal:  Am J Dermatopathol       Date:  2012-04       Impact factor: 1.533

3.  Aortic dissection caused by aortitis associated with hepatitis C virus-related cryoglobulinemia.

Authors:  Naoto Fukunaga; Hiroshi Fujiwara; Michihiro Nasu; Yukikatsu Okada
Journal:  J Thorac Cardiovasc Surg       Date:  2010-08-21       Impact factor: 5.209

4.  Case records of the Massachusetts General Hospital. Case 31-2005. A 60-year-old man with skin lesions and renal insufficiency.

Authors:  Jonathan Kay; Robert T McCluskey
Journal:  N Engl J Med       Date:  2005-10-13       Impact factor: 91.245

5.  Bowel-associated dermatosis-arthritis syndrome. Immune complex-mediated vessel damage and increased neutrophil migration.

Authors:  J L Jorizzo; F C Schmalstieg; S M Dinehart; J C Daniels; T Cavallo; P Apisarnthanarax; H B Rudloff; E B Gonzalez
Journal:  Arch Intern Med       Date:  1984-04

6.  Histopathologic features of erythema nodosum--like lesions in Behçet disease: a comparison with erythema nodosum focusing on the role of vasculitis.

Authors:  B Kim; P E LeBoit
Journal:  Am J Dermatopathol       Date:  2000-10       Impact factor: 1.533

7.  Life-threatening cryoglobulinemia in HCV-negative Southern Chinese and a novel association with structural aortic abnormalities.

Authors:  Wing Y Au; Janette S Y Kwok; Kent M Chu; Edmond S K Ma
Journal:  Ann Hematol       Date:  2004-10-21       Impact factor: 3.673

8.  Vasculitis in erythema induratum of Bazin: a histopathologic study of 101 biopsy specimens from 86 patients.

Authors:  Sonia Segura; Ramón M Pujol; Felicidade Trindade; Luis Requena
Journal:  J Am Acad Dermatol       Date:  2008-11       Impact factor: 11.527

Review 9.  Cutaneous polyarteritis nodosa.

Authors:  José L Díaz-Pérez; Zuriñe Martínez De Lagrán; José Luis Díaz-Ramón; Richard K Winkelmann
Journal:  Semin Cutan Med Surg       Date:  2007-06

10.  2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.

Authors:  J C Jennette; R J Falk; P A Bacon; N Basu; M C Cid; F Ferrario; L F Flores-Suarez; W L Gross; L Guillevin; E C Hagen; G S Hoffman; D R Jayne; C G M Kallenberg; P Lamprecht; C A Langford; R A Luqmani; A D Mahr; E L Matteson; P A Merkel; S Ozen; C D Pusey; N Rasmussen; A J Rees; D G I Scott; U Specks; J H Stone; K Takahashi; R A Watts
Journal:  Arthritis Rheum       Date:  2013-01
View more
  3 in total

Review 1.  [Molecular diagnosis of collagen vascular diseases and vasculitides].

Authors:  K Hoffmann; M Hertl; C Sitaru
Journal:  Hautarzt       Date:  2016-01       Impact factor: 0.751

2.  Demographic characteristics, aetiology, and assessment of treatment options in leukocytoclastic vasculitis.

Authors:  Alkim Unal Cakiter; Ozlem Su Kucuk; Dilek Biyik Ozkaya; Bugce Topukcu; Nahide Onsun
Journal:  Postepy Dermatol Alergol       Date:  2017-04-13       Impact factor: 1.837

3.  Clinical-Pathological Conference Series from the Medical University of Graz : Case No 161: A 42-year-old journalist with fatigue, elevated liver function tests, hyperglycemia and pruritus.

Authors:  Elisabeth Fabian; Markus Peck-Radosavljevic; Elisabeth Krones; Helmut Mueller; Caroline Lackner; Christopher Spreizer; Csilla Putz-Bankuti; Werner Fuerst; Nora Wutte; Peter Fickert; Hansjörg Mischinger; Guenter J Krejs
Journal:  Wien Klin Wochenschr       Date:  2018-08-21       Impact factor: 1.704

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.